Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

about

AFIR: A Dimensionless Potency Metric for Characterizing the Activity of Monoclonal Antibodies.A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.Injectable anti-malarials revisited: discovery and development of new agents to protect against malaria

P2860

Q38856152-26F064F7-9553-42C3-A6A3-70C7B058930F Q42351659-10830203-17A1-42B8-A0A1-DB21A82F3388 Q58566399-2F375A29-63A7-437E-99D2-FC18912D8F49

P2860

Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

Item

http://www.wikidata.org/entity/Q36951905

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

2013年论文

@zh

2013年论文

@zh-cn

name

Factors influencing magnitude ...... rug discovery and development.

@en

type

Item

label

Factors influencing magnitude ...... rug discovery and development.

@en

prefLabel

Factors influencing magnitude ...... rug discovery and development.

@en

P1476

Factors influencing magnitude ...... rug discovery and development.

@en

P2093

Anjaneya P Chimalakonda

http://www.w3.org/2001/XMLSchema#string

Punit Marathe

http://www.w3.org/2001/XMLSchema#string

Rajbharan Yadav

http://www.w3.org/2001/XMLSchema#string

P2860

Use of quantitative pharmacology in the development of HAE1, a high-affinity anti-IgE monoclonal antibody.

From target selection to the minimum acceptable biological effect level for human study: use of mechanism-based PK/PD modeling to design safe and efficacious biologics.

Bridging the gap: facilities and technologies for development of early stage therapeutic mAb candidates

Increasing serum half-life and extending cholesterol lowering in vivo by engineering antibody with pH-sensitive binding to PCSK9

Antibody pharmacokinetics and pharmacodynamics.

On the prediction of the human response: a recycled mechanistic pharmacokinetic/pharmacodynamic approach.

Target-mediated drug disposition and dynamics.

Bridging Clinical Outcomes of Canakinumab Treatment in Patients With Rheumatoid Arthritis With a Population Model of IL-1β Kinetics.

The role of mechanism-based pharmacokinetic-pharmacodynamic (PK-PD) modelling in translational research of biologics.

Monoclonal antibodies as innovative therapeutics.

P2888

s12248-013-9477-3

P304

717-727

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1208/S12248-013-9477-3

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2013-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236185178

http://www.w3.org/2001/XMLSchema#string

P6179

1005269188

http://www.w3.org/2001/XMLSchema#string

P698

23588584

http://www.w3.org/2001/XMLSchema#string

P932

3691422

http://www.w3.org/2001/XMLSchema#string

Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

about

P2860

P2860

Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P932

P356

P1433

P1476

P2093

P2860

P2888

P304

P31

P356

P407

P433

P478

P577

P5875

P6179

P698

P932